1. Nichols N, Townsend R. European Cardiovascular Disease Statistics: European Heart
Network/ European Society of Cardiology. 2012.
2. Farkouh M.E., Domanski M., Sleeper L.A. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 2012. 367 (25):
2375-2384.
3. Serruys W, M.C., Morice A.P. Percutaneous coronary intervention versus coronary-artery bypass graft for Severe Coronary Artery Disease. N Engl J Med. 2009. 360: 961-972.
4. Townsend P, Bhatnagar E. Cardiovascular Disease Statistics. British Heart Foundation, London. 2015.
5. Gruntzig A, Senning W.E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty, N. Engl. J. Med. 1979;
301: 61-68.
6. W. Sapirstein, S. Alpert, T.J. Callahan. The role of clinical trials in the Food and Drug Administration approval process for cardiovascular devices. Circulation. (1994) 1900-1902; 89 -105.
7. S.R. Meyers, M.W. Grinstaff. Biocompatible and bioactive surface modifications for prolonged in vivo efficacy. Chem. Rev. 2012; 112: 140.
8. M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J. Am. Coll. Cardiol. 2006; 48: 193-202.
9. S. Venkatraman, F. Boey. Release profiles in
drug-eluting stents: issues and uncertainties, J. Control. Release. 2007; 120: 149-160.
10. R.A. Byrne, P.W. Serruys, A. Baumbach,
J. Report of a European Society of
Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: an executive summary. Eur. Heart J. 2015; 105-115.
11. R.A. Byrne, M. Joner, A. Kastrati. Polymer coatings and delayed arterial healing following
drug-eluting stent implantation. Minerva Cardioangiol. 2009; 567-584.
12. T.F. Lüscher, J. Steffel, F.R. Eberli, M. Joner, G. Nakazawa, F.C. Tanner, R. Virmani. Drug-eluting stent and coronary thrombosis, biological mechanisms and clinical implications. Circulation .2007; 1051-1058.
13. J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi, G.S. Mintz, S. Nagata. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings, J. Am. Coll. Cardiol.2006; 2108-2111.
14. H.C. Lowe, S.N. Oesterle, L.M. Khachigian. Coronary in-stent restenosis: current status and future strategies. J. Am. Coll. Cardiol.2002; 183-193.
15. G.G. Stefanini, R.A. Byrne, P.W. Serruys, A. de Waha, B. Meier, S. Massberg, P. Jüni, A. Schömig, S. Windecker, A. Kastrati. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISARTEST 4, and LEADERS randomized trials. Eur. Heart J. 2012; 1214-1222.
16. C. Spaulding, J. Daemen, E. Boersma, D.E. Cutlip, P.W. Serruys. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 2007; 356: 989-998.
17. B. Zberg, P.J. Uggowitzer, J.F. Löffler. MgZnCa glasses without clinically observable hydrogen evolution for biodegradable implants. Nat. Mater. 2009; 8: 887-892.
18. R. Zeng, W. Dietzel, F. Witte, N. Hort,
C. Blawert. Progress and challenge for magnesium alloys as biomaterials. Adv. Biomater.2008; 10:
B3-B14.
19. A.J. Nordmann, M. Briel, H.C. Bucher, Mortality in randomized controlled trials comparing
drug-eluting vs. bare metal stents in coronary
artery disease: a meta-analysis, Eur. Heart J. 2006; 2784-2814.
20. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, L. Wallentin. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007;
1009-1019.
21. J.E. Sousa, A.G. Sousa, M.A. Costa. Use of rapamycin-impregnated stents in coronary arteries, Transplant.2003; Proc. 118-124.
22. M.C. Morice, P.W. Serruys, J.E. Sousa. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 2002; 1773-1780.
23. P.W. Serruys, S. Silber, S. Garg. Comparison of zotarolimus-eluting and everolim-useluting coronary stents. N. Engl. J. Med.2010; 136–146.
24. T. Palmerini, G. Biondi-Zoccai, D. Della Riva. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network
meta-analysis. Lancet.2012; 1393-1402.
25. A. Abizaid, J.R. Costa Jr. New drug-eluting stents: an overview on biodegradable and polymer free
next-generation stent systems. Circ. Cardiovasc. Interv.2010; 3: 384-393.
26. M. Haude, S.W. Lee, S.G. Worthley. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc. Interv. 2013; 334-343.
27. M. Natsuaki, K. Kozuma, T. Morimoto, K. Kadota, T. Muramatsu, Y. Nakagawa. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J. Am. Coll. Cardiol. 2013; 181-190.
28. D. Dudek, Y. Onuma, J.A. Ormiston. Four-year clinical follow-up of the absorb everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention .2012; 1060-1061.
29. C. Felix, B. Everaert, R. Diletti, N. Van Mieghem, J. Daemen, M. Valgimigli. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth. Heart J. 2015; 153-160.
30. T. Muramatsu, Y. Onuma, Y.J. Zhang, C.V. Bourantas, A. Kharlamov, R. Diletti. Progress in treatment by percutaneous coronary intervention: the stent of the future. Rev. Esp. Cardiol. 2013;
483-496.
31. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F.R. Eberli. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomized multicentre trial. Lancet .2007; 1869-1875.
32. M. Moravej, D. Mantovani. Biodegradable
metals for cardiovascular stent application:
interests and new opportunities. Int. J. Mol. Sci.2011; 4250-4270.
33. J.E. Schaffer, E.A. Nauman, L.A. Stanciu. Cold drawn bioabsorbable ferrous and ferrous
composite wires: an evaluation of in vitro vascular cytocompatibility. Acta Biomater. 2013;
8574-8584.
34. M. Peuster, P. Wohlsein, M. Brügmann, M. Ehlerding, K. Seidler, C. Fink. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results
6-18 months after implantation into New Zealand white rabbits. Heart 86.2001; 563-569.
35. M. Peuster, C. Hesse, T. Schloo, C. Fink, P. Beerbaum, C. von Schnakenburg. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials. 2006; 4955 4962.
36. D. Pierson, J. Edick, A. Tauscher, E. Pokorney, P. Bowen, J. Gelbaugh. A simplified in vivo approach for evaluating the bioabsorbable behavior of candidate stent materials. J. Biomed. Mater. Res. B Appl. Biomater. 2012; 58-67.
37. Z. Yu, H. Zhu, S. Lu, X. Yang. Accelerated endothelialization with a polymer-free
sirolimus-eluting antibody-coated stent. J. Mater. Sci. Mater. Med.2013; 2601-2609.
38. W.J. Seeto, Y. Tian, E.A. Lipke. Peptide-grafted poly (ethylene glycol) hydrogels support dynamic adhesion of endothelial progenitor cells. Acta Biomater. 2013; 8279-8289.
39. J. Li, D. Li, F. Gong, S. Jiang, H. Yu, Y. An.
Anti-CD133 antibody immobilized on the surface of stents enhances endothelialization. Biomed. Res. Int. 2014; 902782.
40. K. Bonaventura, A.W. Leber, C. Sohns, M. Roser, L.H. Boldt, F.X. Kleber, W. Haverkamp, M. Dorenkamp. Cost-effectiveness of
paclitaxel-coated balloon angioplasty and
paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin. Res. Cardiol. 2012; 573-584.
41. C.W. Hwang, P.V. Johnston, G. Gerstenblith, R.G. Weiss, G.F. Tomaselli, V.E. Bogdan, A. Panigrahi, A. Leszczynska, Z. Xia. Stem cell impregnated nanofiber stent sleeve for on-stent production and intravascular delivery of paracrine factors. Biomaterials 52. 2015; 318-326.
42. K. Nakano, K. Egashira, S. Masuda, K. Funakoshi, G. Zhao, S. Kimura, T. Matoba, K. Sueishi, Y. Endo, Y. Kawashima, K. Hara, H. Tsujimoto, R. Tominaga, K. Sunagawa. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries, J. Am. Coll. Cardiol. Interv. 2009; 277-283.
43. C.L. Song, Q. Li, Y.P. Yu, G. Wang, J.P. Wang, Y. Lu, J.C. Zhang, H.Y. Diao, J.G. Liu, Y.H. Liu, J. Liu, Y. Li, D. Cai, B. Liu. Study of novel coating strategy for coronary stents: simutaneous coating of VEGF and anti-CD34 antibody. Rev. Bras. Cir. Cardiovasc. 2015; 159-163.
44. H. Zhong, O. Matsui, K. Xu, T. Ogi, J. Sanada, Y. Okamoto, Y. Tabata, Y. Takuwa. Gene transduction into aortic wall using plasmid-loaded cationized gelatin hydrogel-coated polyester stent graft. J. Vasc. Surg. 2009; 1433-1443.
45. Y. Liu, W. Wang, G. Acharya, Y.B. Shim, E.S. Choi, C.H. Lee. Advanced stent coating for drug delivery and in vivo biocompatibility. J. Nanopart. Res. 2014; 1-16.
46. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein, J.L. Jaeger, R.E. Kuntz, S. Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003;
1315-1323.
47. M. Santos, M.M.M. Bilek, S.G. Wise.
Plasma-synthesized carbon-based coatings for cardiovascular applications. Biosurf. Biotribol. 2015; 146-160.
48. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 2126-2130.
49. P. Sojitra, C. Engineer, A. Raval, A. Jariwala,
H. Kotadia, D. Kothwala, G. Mehta.
Surface enhancement by novel electrochemical treatment and analysis of L-605 cobalt alloy cardiovascular stent. Trends Biomater. Artif. Organs. 2009; 55-64.
50. R.A. Byrne, P.W. Serruys, A. Baumbach, J. Escaned, J. Fajadet, S. James, M. Joner,S. Oktay, P. Juni, A. Kastrati, G. Sianos, G.G. Stefanini, W. Wijns, S. Windecker. Report of a European society of cardiology-european association of percutaneous cardiovas - cular interventions task force on the evaluation of coronary stents in Europe. Executive summary, Eur. Heart J. 2015; 2608-2620.
51. K. Kolandaivelu, B.B. Leiden, E.R. Edelman. Predicting response to endovascular there- apies: dissecting the roles of local lesion complexity, systemic comorbidity, and clinical uncertainty. J. Biomech. 2014; 908-921.
52. H.-M. Hsiao, Y.-H. Chiu, T.-Y. Wu, J.-K. Shen,
T.-Y. Lee. Effects of through-hole drug reservoirs on key clinical attributes for drug-eluting depot stent. Med. Eng. Phys. 2013; 884-897.
53. C. Liang, Y. Hu, H. Wang, D. Xia, Q. Li, J.
Zhang, J. Yang, B. Li, H. Li, D. Han,
M. Dong. Biomimetic cardiovascular stents for in vivo re-reendothelialization. Biomaterials.
2016; 170-182.
